Solid lipid nanoparticles induced hematological changes and inflammatory response in mice

References

• Aillon KL, Xie Y, El-Gendy N, Berkland CJ, Forrest ML. 2009. Effects of nanomaterial physicochemical properties on in vivo toxicity. Adv Drug Deliv Rev 61(6):457–466.
   PubMed Web of Science ®Google Scholar
• Barlow PG, Donaldson K, MacCallum J, Clouter A, Stone V. 2005. Serum exposed to nanoparticle carbon black displays increased potential to induce macrophage migration. Toxicol Lett 155(3):397–401.
   PubMed Web of Science ®Google Scholar
• Bernardis LL, Patterson BD. 1968. Correlation between 'Lee index' and carcass fat content in weanling and adult female rats with hypothalamic lesions. J Endocrinol 40(4):527–528.
   PubMed Web of Science ®Google Scholar
• Brigger I, Dubernet C, Couvreur P. 2002. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54(5):631–651.
   PubMed Web of Science ®Google Scholar
• Brown SC, Kamal M, Nasreen N, Baumuratov A, Sharma P, Antony VB, et al. 2007. Influence of shape, adhension and simulated lung mechanics on amorphous silica nanoparticle toxicity. Adv Powder Technol 18(1):69–79.
   Web of Science ®Google Scholar
• Chattopadhyay P, Shekunov BY, Yim D, Cipolla D, Boyd B, Farr S. 2007. Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. Adv Drug Deliv Rev 59(6):444–453.
   PubMed Web of Science ®Google Scholar
• Cormode DP, Jarzyna PA, Mulder WJM, Fayad ZA. 2010. Modified natural nanoparticles as contrast agents for medical imaging. Adv Drug Deliv Rev 62(3):329–338.
   PubMed Web of Science ®Google Scholar
• Dianzani C, Cavalli R, Zara GP, Gallicchio M, Lombardi G, Gasco MR, et al. 2006. Cholesteryl butyrate solid lipid nanoparticles inhibit adhesion of human neutrophils to endothelial cells. Br J Pharmacol 148(5):648–656.
   PubMed Web of Science ®Google Scholar
• Fadeel B, Garcia-Bennett AE. 2010. Better safe than sorry: understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. Adv Drug Deliv Rev 62(3):362–374.
   PubMed Web of Science ®Google Scholar
• Faraji AH, Wipf P. 2009. Nanoparticles in cellular drug delivery. Bioorg Med Chem 17(8):2950–2962.
   PubMed Web of Science ®Google Scholar
• Garg DK, Goyal RN. 1992. Hematological and hepatotoxic effects of silken styles of corn in albino-rats. J Appl Toxicol 12(5):359–363.
   PubMed Web of Science ®Google Scholar
• Gratton SE, Ropp PA, Pohlhaus PD, Luft JC, Madden VJ, Napier ME, et al. 2008. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci USA 105(33):11613–11618.
   PubMed Web of Science ®Google Scholar
• Joshi MD, Müller RH. 2009. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 71(2):161–172.
   PubMed Web of Science ®Google Scholar
• Kwon SM, Nam HY, Nam T, Park K, Lee S, Kim K, et al. 2008. In vivo time-dependent gene expression of cationic lipid-based emulsion as a stable and biocompatible non-viral gene carrier. J Control Release 128(1):89–97.
   PubMed Web of Science ®Google Scholar
• Lasagna-Reeves C, Gonzalez-Romero D, Barria MA, Olmedo I, Clos A, Sadagopa Ramanujam VM, et al. 2010. Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice. Biochem Biophys Res Commun 393(4):649–655.
   PubMed Web of Science ®Google Scholar
• Li N, Xia T, Nel AE. 2008. The role of oxidative stress in ambient particulate matter-induced lung diseases and its implications in the toxicity of engineered nanoparticles. Free Radic Biol Med 44(9):1689–1699.
   PubMed Web of Science ®Google Scholar
• Liu J, Gong T, Fu H, Wang C, Wang X, Chen Q, et al. 2008. Solid lipid nanoparticles for pulmonary delivery of insulin. Int J Pharm 356(1-2):333–344.
   PubMed Web of Science ®Google Scholar
• Manjunath K, Venkateswarlu V. 2005. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release 107(2):215–228.
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. 2005. Nanomedicine: current status and future prospects. FASEB J 19(3):311–330.
   PubMed Web of Science ®Google Scholar
• Müller RH, Maaβen S, Weyhers H, Specht F, Lucks JS. 1996. Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. Int J Pharm 138(1):85–94.
   Web of Science ®Google Scholar
• Müller RH, Runge S, Ravelli V, Mehnert W, Thünemann AF, Souto EB. 2006. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm 317(1):82–89.
   PubMed Web of Science ®Google Scholar
• Nguyen DN, Mahon KP, Chikh G, Kim P, Chung H, Vicari AP, et al. 2012. Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery. Proc Natl Acad Sci USA 109(14):E797–E803.
   PubMed Web of Science ®Google Scholar
• Okuda T, Kawakami S, Maeie T, Niidome T, Yamashita F, Hashida M. 2006. Biodistribution characteristics of amino acid dendrimers and their PEGylated derivatives after intravenous administration. J Control Release 114(1):69–77.
   PubMed Web of Science ®Google Scholar
• Olbrich C, Gessner A, Schröder W, Kayser O, Müller RH. 2004. Lipid–drug conjugate nanoparticles of the hydrophilic drug diminazene—cytotoxicity testing and mouse serum adsorption. J Control Release 96(3):425–435.
   PubMed Web of Science ®Google Scholar
• Pantic I. 2011. Nanoparticles and modulation of immune responses. Sci Prog 94(Pt 1):97–107.
   PubMedGoogle Scholar
• Pardeike J, Hommoss A, Müller RH. 2009. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 366(1-2):170–184.
   PubMed Web of Science ®Google Scholar
• Pari L, Murugavel P. 2005. Role of diallyl tetrasulfide in ameliorating the cadmium induced biochemical changes in rats. Environ Toxicol Pharmacol 20(3):493–500.
   PubMed Web of Science ®Google Scholar
• Park EJ, Park K. 2009. Oxidative stress and pro-inflammatory responses induced by silica nanoparticles in vivo and in vitro. Toxicol Lett 184(1):18–25.
   PubMed Web of Science ®Google Scholar
• Petersen S, Steiniger F, Fischer D, Fahr A, Bunjes H. 2011a. The physical state of lipid nanoparticles influences their effect on in vitro cell viability. Eur J Pharm Biopharm 79(1):150–161.
   PubMed Web of Science ®Google Scholar
• Petersen S, Steiniger F, Fischer D, Fahr A, Bunjes H. 2011b. The physical state of lipid nanoparticles influences their effect on in vitro cell viability. Eur J Pharm Biopharm 79(1):150–161.
   PubMed Web of Science ®Google Scholar
• Qi J, Lu Y, Wu W. 2012. Absorption, disposition and pharmacokinetics of solid lipid nanoparticles. Curr Drug Metab 13(4):418–428.
   PubMed Web of Science ®Google Scholar
• Rao SB, Sharma CP. 1997. Use of chitosan as a biomaterial: studies on its safety and hemostatic potential. J Biomed Mater Res 34(1):21–28.
   PubMed Web of Science ®Google Scholar
• Rico CM, Majumdar S, Duarte-Gardea M, Peralta-Videa JR, Gardea-Torresdey JL. 2011. Interaction of nanoparticles with edible plants and their possible implications in the food chain. J Agric Food Chem 59(8):3485–3498.
   PubMed Web of Science ®Google Scholar
• Samuelsen M, Nygaard UC, Løvik M. 2009. Particle size determines activation of the innate immune system in the lung. Scand J Immunol 69(5):421–428.
   PubMed Web of Science ®Google Scholar
• Schöler N, Hahn H, Müller RH, Liesenfeld O. 2002. Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int J Pharm 231(2):167–176.
   PubMedGoogle Scholar
• Semete B, Booysen L, Lemmer Y, Kalombo L, Katata L, Verschoor J, et al. 2010b. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomedicine 6(5):662–671.
   PubMed Web of Science ®Google Scholar
• Semete B, Booysen LI, Kalombo L, Venter JD, Katata L, Ramalapa B, et al. 2010a. In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles. Toxicol Appl Pharmacol 249(2):158–165.
   PubMed Web of Science ®Google Scholar
• Silva AH, Filippin-Monteiro FB, Mattei B, Zanetti-Ramos BG, Creczynski-Pasa TB. 2012. In vitro biocompatibility of solid lipid nanoparticles. Sci Total Environ 432C:382–388.
   Google Scholar
• Stebounova LV, Adamcakova-Dodd A, Kim JS, Park H, O'Shaughnessy PT, Grassian VH, et al. 2011. Nanosilver induces minimal lung toxicity or inflammation in a subacute murine inhalation model. Part Fibre Toxicol 8(1):5.
   PubMed Web of Science ®Google Scholar
• Stern ST, McNeil SE. 2008. Nanotechnology safety concerns revisited. Toxicol Sci 101(1):4–21.
   PubMed Web of Science ®Google Scholar
• Wan F, You J, Sun Y, Zhang X-G, Cui F-D, Du Y-Z, et al. 2008. Studies on PEG-modified SLNs loading vinorelbine bitartrate (I): Preparation and evaluation in vitro. Int J Pharm 359(1–2):104–110.
   PubMedGoogle Scholar
• Wang JJ, Liu KS, Sung KC, Tsai CY, Fang JY. 2009. Lipid nanoparticles with different oil/fatty ester ratios as carriers of buprenorphine and its prodrugs for injection. Eur J Pharm Sci 38(2):138–146.
   PubMed Web of Science ®Google Scholar
• Wang M, Thanou M. 2010. Targeting nanoparticles to cancer. Pharmacol Res 62(2):90–99.
   PubMed Web of Science ®Google Scholar
• Weyhers H, Ehlers S, Hahn H, Souto EB, Müller RH. 2006. Solid lipid nanoparticles (SLN)–effects of lipid composition on in vitro degradation and in vivo toxicity. Pharmazie 61(6):539–544.
   PubMed Web of Science ®Google Scholar
• Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. 2007. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 59(6):491–504.
   PubMed Web of Science ®Google Scholar
• Wong HL, Rauth AM, Bendayan R, Manias JL, Ramaswamy M, Liu Z, et al. 2006. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res 23(7):1574–1585.
   PubMed Web of Science ®Google Scholar
• Wu W, Chen B, Cheng J, Wang J, Xu W, Liu L, et al. 2010. Biocompatibility of Fe3O4/DNR magnetic nanoparticles in the treatment of hematologic malignancies. Int J Nanomedicine 5:1079–1084.
   PubMed Web of Science ®Google Scholar
• Yuan H, Zhang W, Du YZ, Hu FQ. 2010. Ternary nanoparticles of anionic lipid nanoparticles/protamine/DNA for gene delivery. Int J Pharm 392(1-2):224–231.
   PubMedGoogle Scholar